Identifying tumor-specific neoantigens for cancer immunotherapy
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
This study is working on a new way to find special markers on cancer cells that help your immune system fight the disease, with the goal of making cancer treatments more personalized and effective for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11049090 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to identify neoantigens, which are unique markers on cancer cells that can be targeted by the immune system. By combining advanced genomic sequencing, bioinformatics, and a novel mass spectrometry technique, the project aims to improve the accuracy of neoantigen detection. This approach seeks to enhance the effectiveness of cytotoxic T-lymphocyte-based immunotherapies, potentially leading to more personalized and effective cancer treatments for patients. The research involves collaboration between academic and industrial partners to create a practical pipeline for clinical use.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with tumors that have unique neoantigens, particularly those who are considering or currently undergoing immunotherapy.
Not a fit: Patients with cancers that do not express identifiable neoantigens or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that specifically target individual tumors, improving patient outcomes.
How similar studies have performed: Other research has shown promise in using similar bioinformatics and mass spectrometry approaches for neoantigen identification, indicating potential for success in this novel pipeline.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Reinherz, Ellis L — Dana-Farber Cancer Inst
- Study coordinator: Reinherz, Ellis L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.